Association between patient adherence and treat-to-target in gout: A cross-sectional study

Shasha Hu,Sihui He,Jianyong Zhang,Wukai Ma,Hongling Geng,Zhiying Zhan,Xueming Yao,Li Zhong,Jiaxin Wei,Xia Qiu,Ertao Jia
DOI: https://doi.org/10.1097/md.0000000000037228
IF: 1.6
2024-02-25
Medicine
Abstract:Gout, a prevalent arthritic condition, arises from the deposition of monosodium urate crystals. In the United States, gout affects approximately 3% to 4% of adults. [ 1 ] The purpose of gout treatment is to quickly and effectively relieve and eliminate acute symptoms, prevent the recurrence of acute arthritis, and reduce serum uric acid (sUA). [ 2 ] Nonsteroidal anti-inflammatory drugs are an important option in gout acute attacks, which can provide both anti-inflammation and analgesia. [ 3–5 ] For patients with gout, urate-lowering treatment (ULT) is imperative, as it mitigates the frequency of gout attacks, reduces the involvement of joints, diminishes urate deposition, and safeguards articular cartilage and renal function. [ 6 ] Notably, the American College of Rheumatology (ACR) released guidelines in 2020 advocating for the treat-to-target (T2T) strategy in gout treatment. [ 7 ] These recent guidelines provide clinicians with directives on managing gout cases within the framework of a T2T approach. Specifically, the treatment guidelines endorse striving for a sUA target of <360 μmoI/L for all gout patients and <300 μmoI/L for those afflicted with tophaceous or severe gout. [ 8 , 9 ] However, a prevalence study revealed that only 22.3% of patients reached the stipulated target level, with the rate dwindling to a mere 11% for those on ULT for more than 12 months. [ 10 ]
medicine, general & internal
What problem does this paper attempt to address?